Search

Your search keyword '"Kobashi, Gen"' showing total 23 results
Start Over Author "Kobashi, Gen" Publisher wiley
23 results on '"Kobashi, Gen"'

5. Psychological stress among pregnant and puerperal women in Japan during the coronavirus disease 2019 pandemic

Author

Obata, Soichiro, primary, Miyagi, Etsuko, additional, Haruyama, Yasuo, additional, Umazume, Takeshi, additional, Kobashi, Gen, additional, Yoshimi, Asuka, additional, Hishimoto, Akitoyo, additional, Kurasawa, Kentaro, additional, Suzuki, Yukio, additional, Ikeda, Tomoaki, additional, Kimura, Tadashi, additional, and Yamada, Hideto, additional

Published
2021
Full Text
View/download PDF

10. Diagnostic value of a nested polymerase chain reaction for diagnosing cutaneous sporotrichosis from paraffin‐embedded skin tissue

Author

Hayashi, Shujiro, primary, Kaminaga, Tomoko, additional, Baba, Akiko, additional, Koike, Saiko, additional, Koike, Masami, additional, Kanno, Miki, additional, Ishikawa, Satoko, additional, Tsukada, Kyoujyu, additional, Suzuki, Toshihiro, additional, Hamasaki, Yoichiro, additional, Sairenchi, Toshimi, additional, Kobashi, Gen, additional, and Igawa, Ken, additional

Published
2019
Full Text
View/download PDF

11. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy

Author

Kasuya, Goro, Ishikawa, Hitoshi, Tsuji, Hiroshi, Nomiya, Takuma, Makishima, Hirokazu, Kamada, Tadashi, Akakura, Koichiro, Suzuki, Hiroyoshi, Shimazaki, Jun, Haruyama, Yasuo, Kobashi, Gen, and Tsujii, Hirohiko

Abstract

BACKGROUND: Whether biochemical recurrence (BR) is a significant predictive factor of mortality after definitive radiation therapy for prostate cancer remains unknown. The aim of the current study was to investigate the relation between BR and overall mortality (OAM) in high-risk prostate cancer patients who were treated with carbon-ion radiotherapy (CIRT) and had long-term follow-up in 2 prospective trials. METHODS: In the 2 phase 2 clinical trials, which involved 466 prostate cancer patients who received 63.0 to 66.0 Gy of CIRT (relative biological effect) in 20 fractions between 2000 and 2007, 324 patients who were deemed to be at high risk on the basis of the modified D'Amico classification criteria and received CIRT along with androgen-deprivation therapy (ADT) were examined. The OAM rate was adjusted for the ADT duration, and multivariate analyses using a Cox proportional hazards model were performed for OAM with BR as a time-dependent covariate. RESULTS: The median follow-up period was 107.4 months, and the 5- and 10-year OAM rates after adjustments for the ADT duration were 7.0% (95% confidence interval [CI], 4.0%-9.4%) and 23.9% (95% CI, 16.4%-26.2%), respectively. A multivariate analysis revealed that the presence of BR (hazard ratio, 2.82; 95% Cl, 1.57-5.08; P = .001) was one of the predictive factors for OAM. On the other hand, the duration of ADT had no impact on OAM. CONCLUSIONS: BR after CIRT combined with ADT is an independent predictive factor for OAM in high-risk prostate cancer patients. The results of this study could be applied to other high-dose radiation therapies. Cancer 2016. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

Published
2016

22. Poor uterine contractility and postpartum hemorrhage among low-risk women: A case-control study of a large-scale database from Japan.

Author

Nishida K, Sairenchi T, Uchiyama K, Haruyama Y, Watanabe M, Hamada H, Satoh T, Miyashita S, Fukasawa I, and Kobashi G

Subjects
Adult, Case-Control Studies, Female, Humans, Japan, Pregnancy, Risk Factors, Uterus metabolism, Young Adult, Labor, Obstetric, Postpartum Hemorrhage etiology
Abstract

Objective: To examine the association between the risk of postpartum hemorrhage (PPH) and poor uterine contractility, which is suggested by the characteristics of labor., Methods: This case-control study used cases recorded in the Japan Perinatal Registry database during the period 2013-2016. After exclusion of women with specified known risk factors for PPH, we enrolled 174 082 primiparas who had a full-term live singleton vaginal birth. Participants were classified into four classes according to the diagnosis of abnormal labor patterns and use of uterotonics. χ 2 tests were used to compare PPH cases with controls, and odds ratios (OR) were calculated by univariate and multivariate analyses., Results: Among the enrolled women, 10 508 (6.0%) had PPH. Abnormal labor patterns were significantly associated with an increased risk of PPH. Compared with women without any abnormal labor patterns who had not used uterotonics, women with abnormal labor patterns were at a significantly increased risk for PPH regardless of whether they had used uterotonics (adjusted OR 1.23, 95% confidence interval [CI] 1.10-1.37) or not (adjusted OR 1.30, 95% CI 1.23-1.37)., Conclusion: Our study suggests that among low-risk women with PPH, poor uterine contractility in labor could be a significant predisposing risk factor for PPH., (© 2020 International Federation of Gynecology and Obstetrics.)

Published
2021
Full Text
View/download PDF

23. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.

Author

Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H, Miyazaki M, Kamada T, and Tsujii H

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular mortality, Female, Humans, Liver Neoplasms mortality, Male, Maximum Tolerated Dose, Middle Aged, Mortality, Multivariate Analysis, Radiation Dose Hypofractionation, Severity of Illness Index, Thrombosis epidemiology, Carcinoma, Hepatocellular radiotherapy, Heavy Ion Radiotherapy methods, Liver Neoplasms radiotherapy
Abstract

Background: The objective of this study was to evaluate the safety and efficacy of carbon-ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC) with stepwise dose escalation and hypofractionation in 2 combined prospective trials., Methods: Sequential phase 1/2 (protocol 9603) and phase 2 (protocol 0004) trials were conducted for patients with histologically proven HCC. The phase 1 component of protocol 9603 was a dose-escalation study; CIRT was delivered in 12, 8, or 4 fractions. After determination of the recommended dose, 2 phase 2 trials were performed in an expanded cohort, and the data were pooled to analyze toxicity, local control, and overall survival., Results: In the phase 1 component of protocol 9603, 69.6, 58.0, and 52.8 Gy (relative biological effectiveness [RBE]) in 12, 8, and 4 fractions, respectively, constituted the maximum tolerated doses, and 52.8 Gy (RBE) in 4 fractions was established as the recommended dose regimen for the 2 phase 2 studies. In 124 patients with a total of 133 lesions, few severe adverse effects occurred, and local-control and overall survival rates at 1, 3, and 5 years were 94.7% and 90.3%, 91.4% and 50.0%, and 90.0% and 25.0%, respectively; this included 1-, 3-, and 5-year local-control rates of 97.8%, 95.5%, and 91.6%, respectively, in the phase 2 study. In a multivariate analysis, Child-Pugh class B and the presence of a tumor thrombus were significant factors for mortality., Conclusions: The safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017;123:3955-65. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society., (© 2017 The Authors. Cancer published by Wiley Periodicals, Inc.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results